Washington, Oct 19 (EFE).- The United States on Wednesday approved the use of Novavax’s Covid-19 vaccine as a booster for adults.
Novavax thus joins Pfizer-BioNTech and Moderna, which already have the US Food and Drug Administration approval for booster doses.
The FDA granted Novavax emergency authorization, and the Centers for Disease Control and Prevention (CDC) immediately responded with its approval.
“The Novavax Covid-19 Vaccine, Adjuvanted is authorized for emergency use to provide a first booster dose to individuals 18 years of age and older for whom an FDA-authorized mRNA bivalent1 Covid-19 booster vaccine is not accessible or clinically appropriate,” the drug authority said.
The Novavax booster dose can be received six months after completing the initial regimen of any other vaccine, be it Pfizer-BioNTech, Moderna, Johnson&Johnson or Novavax itself.
Novavax’s vaccine is based on traditional technology and has been created with protein-based methods.
The US granted emergency authorization for the use of Novavax’s Covid-19 vaccine in its initial dose in July, which became the fourth such serum to be approved in the country. EFE